The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Open accessAbstract
The cognitive hallmark of early Alzheimer's disease (AD) is an extraordinary inability to form new memories. For many years, this dementia was attributed to nerve-cell death induced by deposits of fibrillar amyloid beta (Abeta). A newer hypothesis has emerged, however, in which early memory loss is considered a synapse failure caused by soluble Abeta oligomers. Such oligomers rapidly block long-term potentiation, a classic experimental paradigm for synaptic plasticity, and they are strikingly elevated in AD brain tissue and transgenic-mouse AD models. The current work characterizes the manner in which Abeta oligomers attack neurons. Antibodies raised against synthetic oligomers applied to AD brain sections were found to give diffuse stain around neuronal cell bodies, suggestive of a dendritic pattern, whereas soluble brain extracts showed robust AD-dependent reactivity in dot immunoblots. Antigens in unfractionated AD extracts attached with specificity to cultured rat hippocampal neurons, binding within dendritic arbors at discrete puncta. Crude fractionation showed ligand size to be between 10 and 100 kDa. Synthetic Abeta oligomers of the same size gave identical punctate binding, which was highly selective for particular neurons. Image analysis by confocal double-label immunofluorescence established that >90% of the punctate oligomer binding sites colocalized with the synaptic marker PSD-95 (postsynaptic density protein 95). Synaptic binding was accompanied by ectopic induction of Arc, a synaptic immediate-early gene, the overexpression of which has been linked to dysfunctional learning. Results suggest the hypothesis that targeting and functional disruption of particular synapses by Abeta oligomers may provide a molecular basis for the specific loss of memory function in early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite ongoing debate, Aβ accumulation, whether in the form of insoluble plaques, or smaller soluble oligomers does appear to be a primary driver of the disease process, particularly linked to synapse dysfunction [3].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, overexpression of APP and its proteolytic product, Aβ, have been implicated in the synaptic losses seen early in the development of AD [27].”
From FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein (2007) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other suggested Aβ binding partners at synapses include the α7-nicotinic receptor [49], Ephrin A4 [73], PSD95 [35, 50, 52] and LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“As previously discussed, amyloid-β oligomers bind to synapses [144] and interfere with the normal process of neurotransmission, long-term potentiation, and thereby memory formation [145].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [144]
In the citing paper
“Immunohistochemistry confirms that oligomers associate with neurons, accumulating very early in disease progression (Lacor et al., 2004), in loci distinct from amyloid deposits (Kayed et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The possible source of extracellular oligomers and how they interact with neurons in human brain are suggested by their peri-somatic localization, observed in early-stage disease (Figure 1, left; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“The same binding specificity and punctate pattern is observed for synthetic oligomers, particularly those greater than 50 kDa (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Oligomers show > 90% co-localization with the post-synaptic marker PSD-95 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“This prediction was first confirmed for NMDA-Rs (Lacor et al., 2004; Lacor et al., 2007; Snyder et al., 2005).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“One rapid consequence is an aberrant expression of Arc (Activity-Regulated Cytoskeletal associated protein; (Lacor et al., 2004)).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“Coupled with the potential of dendrites for activity-stimulated exocytosis (Kennedy et al., 2010), such a phenomenon could account for the “perineuronal deposits” of oligomers seen in Figure 1 (Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lacor et al., 2004
In the citing paper
“All of these processes are affected by Aβ oligomers in vitro, using primary neuronal cultures (12, 15, 36, 37).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [37]
In the citing paper
“Furthermore, extracellular Aβ1-42 oligomers preferentially target synapses when added to neurons [43, 91].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [91]
In the citing paper
“Other binding partners that have been suggested to bind Aβ include the α7-nicotinic receptor [49], Ephrin A4 (EphA4) [73], PSD95 [35, 50, 52] or LilrB2 [32].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Research works printed but not linked: 2
- Klein WL (2004) Cytotoxic intermediates in the fibrillation pathway: Aβ oligomers in Alzheimer's disease as a case study. In: Protein misfolding, aggregation and conformational diseases (Uversky V, ed). New York: Kluwer Academic/Plenum, in press.
- 2002, Nat Rev Neurosci, 3, 824
Cited by
Sorted by citations
Items 701–800 of 949
Ng, A. N., Salter, E. W., Georgiou, J., Bortolotto, Z. A., & Collingridge, G. L. (2023) · iScience · doi:10.1016/j.isci.2023.108412 · Cited by 16
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting
Sandoval, K. E., & WITT, K. A. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001117 · Cited by 14
Anchored FRET sensors detect local caspase activation prior to neuronal degeneration
Figueroa, R. A., Ramberg, V., Gatsinzi, T., Samuelsson, M., Zhang, M., Iverfeldt, K., & Hallberg, E. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-35 · Cited by 14
Amyloid-β Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena
Marcello, E. E., Musardo, S., Vandermeulen, L., Pelucchi, S., Gardoni, F., Santo, N., Antonucci, F., & Luca, M. D. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1583-5 · Cited by 14
Whiteaker, P., & George, A. A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106743 · Cited by 14
Upadhaya, A. R., Scheibe, F., Kosterin, I., Abramowski, D., Gerth, J., Kumar, S., Liebau, S., Yamaguchi, H., Walter, J., Staufenbiel, M., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-77 · Cited by 14
Bartley, S. C., Proctor, M. T., Xia, H., Ho, E., Kang, D. S., Schuster, K. H., Bicca, M. A., Seckler, H. S., Viola, K. L., Patrie, S. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042208 · Cited by 14
Self-citationTaking STEPs Forward to Understand Fragile X Syndrome
Goebel-Goody, S. M., & Lombroso, P. J. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_12 · Cited by 14
Sebastià, J., Pertusa, M., Vı́lchez, D., Planas, A. M., Verbeek, R., Rodrı́guez-Farré, E., Cristòfol, R. M., & Sanfeliu, C. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0492-8 · Cited by 14
Colin, J., Allouche, A., Chauveau, F., Corbier, C., Gregory, L., Lanhers, M., Claudepierre, T., Yen, F. T., Oster, T., & Malaplate, C. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151110 · Cited by 14
Zhang, X., Wang, W.-A., Jiang, L.-X., Liu, H., Zhang, B., Lim, N. K.-H., Li, Q.-Y., & Huang, F.-D. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3567-16.2017 · Cited by 14
Savioz, A., Giannakopoulos, P., Herrmann, F. R., Klein, W. L., Kövari, E., Bouras, C., & Giacobini, E. (2016) · Neurodegenerative Diseases · doi:10.1159/000446283 · Cited by 14
Self-citationHou, X., Jin, Y., Chen, J., Hong, Y., Luo, D., Yin, Q., & Liu, X. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.012 · Cited by 13
Lantz, M. J., Roberts, A. M., Delgado, D. D., & Nichols, R. A. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02807-9 · Cited by 13
Cell Surface Binding and Internalization of Aβ Modulated by Degree of Aggregation
Bateman, D. A., & Chakrabartty, A. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/962352 · Cited by 13
A mix-and-click method to measure amyloid-β concentration with sub-micromolar sensitivity
Xue, C., Lee, Y. K., Tran, J., Chang, D., & Guo, Z. (2017) · Royal Society Open Science · doi:10.1098/rsos.170325 · Cited by 13
Role of the SNK‐SPAR pathway in the development of Alzheimer's disease
Gong, X., Lu, X.-G., Zhan, L., Sui, H. X., Qi, X., Zheng-hong, J., Niu, X., & Liu, L. (2010) · IUBMB Life · doi:10.1002/iub.308 · Cited by 14
The neurodegeneration in Alzheimer disease and the prion protein
Forloni, G., Sclip, A., Borsello, T., & Balducci, C. (2013) · Prion · doi:10.4161/pri.23286 · Cited by 13
Watremez, W., Jackson, J. D., Almari, B., McLean, S. L., Grayson, B., Neill, J. C., Fischer, N., Allouche, A., Koziel, V., Pillot, T., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170489 · Cited by 13
Acetylation of Aβ 40 Alters Aggregation in the Presence and Absence of Lipid Membranes
Pilkington, A. W., Schupp, J. E., Nyman, M., Valentine, S. J., Smith, D. M., & Legleiter, J. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00483 · Cited by 12
Matsubara, E., Takamura, A., Okamoto, Y., Oono, H., Nakata, T., Wakasaya, Y., Kawarabayashi, T., & Shoji, M. (2013) · BioMed Research International · doi:10.1155/2013/984041 · Cited by 12
Mozzoni, K., Limegrover, C. S., Rehak, C., Yurko, R., Izzo, N. J., Knezovich, N., Watto, E., Waybright, L., & Catalano, S. M. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109180 · Cited by 12
Mollinari, C., Cardinale, A., Lupacchini, L., Martire, A., Chiodi, V., Martinelli, A., Rinaldi, A. M., Fini, M., Pazzaglia, S., Domenici, M. R., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00198-3 · Cited by 12
Cacciaglia, R., Falcón, C., Sánchez‐Benavides, G., Brugulat‐Serrat, A., Alomà, M. M., Suárez‐Calvet, M., Molinuevo, J. L., Fauria, K., Minguillón, C., Kollmorgen, G., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14415 · Cited by 14
Dynamic properties of pH-dependent structural organization of the amyloidogenic β-protein (1-40)
Rubinstein, A. I., Lyubchenko, Y. L., & Sherman, S. (2009) · Prion · doi:10.4161/pri.3.1.8388 · Cited by 11
Takamura, A., Kawarabayashi, T., Yokoseki, T., Shibata, M. S., Morishima‐Kawashima, M., Saito, Y., Murayama, S., Ihara, Y., Abe, K., Shoji, M., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22615 · Cited by 11
Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts
Mousa, Y. M., Abdallah, I. M., Hwang, M., Martin, D. R., & Kaddoumi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60664-5 · Cited by 11
Manap, A. S. A., Madhavan, P., Vijayabalan, S., Chia, A. Y. Y., & Fukui, K. (2020) · PeerJ · doi:10.7717/peerj.10003 · Cited by 11
Actor-Engel, H. S., Schwartz, S. L., Crosby, K. C., Sinnen, B. L., Prikhodko, O., Ramsay, H. J., Bourne, J. N., Winborn, C. S., Lucas, A., Smith, K. R., et al. (2021) · eNeuro · doi:10.1523/eneuro.0416-21.2021 · Cited by 11
Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
Rådestig, M. A., Skoog, I. G., Skillbäck, T. B., Zetterberg, H., Kern, J., Zettergren, A., Andréasson, U., Wetterberg, H., Kern, S., & Blennow, K. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01193-x · Cited by 11
Sun, X., Wu, W., Liu, Q. R., Chen, M., Yu, Y., Ma, Y., Zhao, Y., & Li, Y. (2009) · Peptides · doi:10.1016/j.peptides.2009.04.012 · Cited by 11
Effect of pharmacological manipulations on Arc function
Yakout, D. W., Ramesh, N. S., & Mabb, A. M. (2020) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2020.100013 · Cited by 11
Banchelli, M., Cascella, R., D’Andrea, C., Penna, G. L., Li, M. S., Machetti, F., Matteini, P., & Pizzanelli, S. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00714 · Cited by 11
Tweedie, D., Brossi, A. R., Chen, D., Ge, Y., Bailey, J. A., Yu, Q.-S., Kamal, M. A., Sambamurti, K., Lahiri, D. K., & Greig, N. H. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10102 · Cited by 11
A common pathway for detergent-assisted oligomerization of Aβ42
Muhammedkutty, F. N. K., Prasad, R., Gao, Y., Sudarshan, T. R., Robang, A. S., Watzlawik, J. O., Rosenberry, T. L., Paravastu, A. K., & Zhou, H. (2023) · Communications Biology · doi:10.1038/s42003-023-05556-w · Cited by 10
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10
Behroozi, Z., Askarpour, H., & Baghcheghi, Y. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261415807 · Cited by 10
Mechanisms of Microglial Activation by Amyloid Precursor Protein and its Proteolytic Fragments
Austin, S. A., & Combs, C. K. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_2 · Cited by 10
Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
Creed, M. C., & Milgram, N. W. (2010) · AGE · doi:10.1007/s11357-010-9142-z · Cited by 10
Feng, B., Hu, P., Lü, S., Wang, R., & Du, Y. (2014) · Europe PMC (PubMed Central) · Cited by 10
Immune Responses to Herpesviral Vectors
Ryan, D. A., & Federoff, H. J. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.019 · Cited by 10
REELIN ameliorates Alzheimer's disease, but how?
Katsuyama, Y., & Hattori, M. (2024) · Neuroscience Research · doi:10.1016/j.neures.2024.07.004 · Cited by 9
Vogler, L., Ballweg, A., Bohr, B., Briel, N., Wind-Mark, K., Antons, M. J., Kunze, L. H., Gnörich, J. S., Lindner, S., Gildehaus, F., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103484 · Cited by 11
Ahuja, M., Patel, M., Majrashi, M., Mulabagal, V., & Dhanasekaran, M. (2017) · Medicinal and aromatic plants of the world · doi:10.1007/978-981-10-5978-0_1 · Cited by 9
The phospholipase A2 pathway controls a synaptic cholesterol ester cycle and synapse damage
Osborne, C., West, E., & Bate, C. (2018) · Journal of Cell Science · doi:10.1242/jcs.211789 · Cited by 9
SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology
Lee, A. K., Yi, N., Khaled, H., Feller, B., Chofflet, N., & Takahashi, H. (2023) · Life Science Alliance · doi:10.26508/lsa.202201681 · Cited by 11
Shen, J., Wang, D., & Wang, R. (2012) · PubMed Central · Cited by 9
The Microtubule-Associated Protein 1A (MAP1A) is an Early Molecular Target of Soluble Aβ-Peptide
Clemmensen, C., Aznar, S., Knudsen, G. M., & Klein, A. B. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9796-9 · Cited by 9
Rethinking Alzheimer’s disease: The role of age-related changes
Drachman, D. A. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0040-4 · Cited by 9
The Aged Dog as a Natural Model of Alzheimer’s Disease Progression
Araujo, J. A., Baulk, J., & de Rivera, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53219-6_4 · Cited by 9
Advances in our Understanding of Neurodegeneration
Jellinger, K. A. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50142-3 · Cited by 9
Aisen, P. S. S. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.08.004 · Cited by 9
Parker, E. M., Kindja, N. L., DeGiosio, R. A., Salisbury, R., Krivinko, J. M., Cheetham, C. E. J., MacDonald, M. L., Fan, W., Cheng, B., & Sweet, R. A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03181-7 · Cited by 8
Randhawa, S., Saini, T. C., Bathla, M., Bhardwaj, R., Dhiman, R., & Acharya, A. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.44 · Cited by 8
Marshall, K. E., Mengham, K., Spink, M. C., Vania, L., Pollard, H. J., Darrow, M. C., Duke, E., Harkiolaki, M., & Serpell, L. C. (2024) · Structure · doi:10.1016/j.str.2024.02.010 · Cited by 8
Intracellular Cleavage of Amyloid β by a Viral Protease NIa Prevents Amyloid β-Mediated Cytotoxicity
Shin, B., Oh, H., Park, S. M., Han, H.-E., Ye, M., Song, W. K., & Park, W. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098650 · Cited by 8
Pascual, A. C., Gaveglio, V. L., Giusto, N. M., & Pasquaré, S. J. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.08.042 · Cited by 8
Agnati, L. F., Leo, G., Genedani, S., Piron, L., Rivera, A., Guidolin, D., & Fuxé, K. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0150-4 · Cited by 8
Cargo trafficking in Alzheimer’s disease: the possible role of retromer
Sadigh‐Eteghad, S., Askari-Nejad, M. S., Mahmoudi, J., & Majdi, A. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2399-3 · Cited by 8
The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease
Bhaskar, K., & Lamb, B. T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_5 · Cited by 8
Developing BACE-1 inhibitors for FXS
Westmark, C. J., Berry‐Kravis, E., Ikonomidou, C., Yin, J. C. P., & Puglielli, L. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00077 · Cited by 8
LeVine, H., & Walker, L. C. (2006) · Elsevier eBooks · doi:10.1016/b978-012369391-4/50012-6 · Cited by 8
Alzheimer's Disease: Reducing the burden with ApoE2
Federoff, H. J. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302522 · Cited by 8
Fernández‐Fernández, D., Dorner‐Ciossek, C., Kroker, K. S., & Rosenbrock, H. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23701 · Cited by 7
Cline, E. N., Antwi‐Berko, D., Sundell, K. L., Johnson, E. A., Hyland, M., Zhang, H., Vanderstichele, H., Kaplow, J. M., Dean, R. A., Stoops, E., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100082 · Cited by 8
Challenges in understanding the structure/activity relationship of Aβ oligomers
Pilkington, A. W., & Legleiter, J. A. (2019) · AIMS Biophysics · doi:10.3934/biophy.2019.1.1 · Cited by 7
Guo, Q., Wu, G., Huang, F., Wei, Z. C., Wang, J., Zhang, B., Liu, R., Yang, Y., Wang, X., & Li, H. (2022) · Aging · doi:10.18632/aging.204336 · Cited by 7
Célestine, M., Jacquier‐Sarlin, M. R., Borel, E., Petit, F., Pérot, J., Hérard, A., Bousset, L., Buisson, A., & Dhénain, M. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01559-0 · Cited by 7
Bouvet, P., Gea, P. D., Aimard, M., Chounlamountri, N., Honnorat, J., Delcros, J., Salin, P. A., & Meissirel, C. (2023) · Aging Cell · doi:10.1111/acel.13907 · Cited by 9
Protective effects of EUK4010 on β‐amyloid(1–42) induced degeneration of neuronal cells
Sun, L., Wang, L., Sun, Y., Tang, S., & Hu, Y. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04951.x · Cited by 7
Weidner, A. M., Smith, M. H., Murphy, M. P., & LeVine, H. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.03.082 · Cited by 7
Why Alzheimer’s is a Disease of Memory: Synaptic Targeting by Pathogenic Aβ Oligomers (ADDLs)
Klein, W. L., Felice, F. G. D., Lacor, P. N., Lambert, M. P., & Zhao, W.-Q. (2008) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-540-76330-7_9 · Cited by 7
Self-citationAmyloid Beta, TNFα and FAIM-L; Approaching New Therapeutic Strategies for AD
Carriba, P., & Comella, J. X. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00276 · Cited by 7
Howell, N., Dykens, J. A., & Moos, W. H. (2005) · Drug Development Research · doi:10.1002/ddr.20046 · Cited by 7
Tahiroğlu, V., Uğur, E., COŞKUN, E., Alayunt, N. Ö., & Zorgör, G. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/172012 · Cited by 6
Aβ Oligomers-Induced Toxicity is Attenuated in Cells Cultured with NbActiv4™ Medium
Zhou, Y., & Klein, W. L. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9318-7 · Cited by 6
Self-citationMustata, G.-M., Shekhawat, G. S., Lambert, M. P., Viola, K. L., Velasco, P. T., Klein, W. L., & Dravid, V. P. (2012) · Applied Physics Letters · doi:10.1063/1.3697682 · Cited by 6
Self-citationOligomerization and toxicity of Aβ fusion proteins
Caine, J. M., Bharadwaj, P. R., Sankovich, S. E., Ciccotosto, G. D., Streltsov, V. A., & Varghese, J. N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.05.029 · Cited by 6
Verdier, Y., & Penke, B. (2006) · Current Signal Transduction Therapy · doi:10.2174/157436206775269208 · Cited by 6
On the key role played by altered protein conformation in Parkinson’s disease
Agnati, L. F., Baldelli, E., Andreoli, N., Woods, A. S., Vellani, V., Marcellino, D. J., Guidolin, D., & Fuxé, K. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0072-1 · Cited by 6
Kawarabayashi, T., Terakawa, T., Takahashi, A., Hasegawa, H., Narita, S., Sato, K., Nakamura, T., Seino, Y., Hirohata, M., Baba, N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190023 · Cited by 6
Synaptic scaffold protein PSD-95: a therapeutic target for Alzheimer’s disease
Fan, X., Wang, H., Ping, J., Li, M., Gu, J., & Qian, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117401 · Cited by 8
Jaye, S., Sandau, U. S., McFarland, T. J., Woltjer, R. L., & Saugstad, J. A. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1426180 · Cited by 5
Wiseman, J. P., Basit, R. H., Suto, A., Middya, S., Kabiri, B., Evans, M. G., George, V. T., Adams, C., Malliaras, G. G., & Chari, D. M. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00422 · Cited by 5
Alzheimer’s Disease and Diabetes
Brent, D. A., Gary, L., Aboud, Z., & Gordon, W. (2013) · InTech eBooks · doi:10.5772/54913 · Cited by 6
Guerreiro, N., Gomez‐Mancilla, B., Williamson, B., Minkoff, M., & Guertin, S. (2009) · Clinical Proteomics · doi:10.1007/s12014-009-9030-7 · Cited by 5
John, P. A. S. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21251 · Cited by 5
Lee, J., & Kwag, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00901-9 · Cited by 4
Kang, C., Park, M., & Lee, H. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00401-x · Cited by 4
Johnson, E. A., Nowar, R., Viola, K. L., Huang, W., Zhou, S., Bicca, M. A., Zhu, W., Kranz, D. L., Klein, W. L., & Silverman, R. B. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402117122 · Cited by 5
Self-citationPreclinical MRI and NMR Biomarkers of Alzheimer's Disease: Concepts and Applications
Dhénain, M. (2008) · Magnetic Resonance Insights · doi:10.4137/mri.s971 · Cited by 4
Bitan, F. R. A. G. (2014) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608058525114020014 · Cited by 4
Zhao, W., Toolan, D. M., Hepler, R. W., Wolfe, A. L., Yu, Y., Price, E. A., Uebele, V. N., Schachter, J. B., Reynolds, I. J., Renger, J. J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102022 · Cited by 4
Differential effects of amyloid-beta peptide aggregation status on in vivo retinal neurotoxicity
Watts, H. R. (2010) · Eye and Brain · doi:10.2147/eb.s9902 · Cited by 4
Prospects and Challenges for Alzheimer Therapeutics
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00023-x · Cited by 5
Powers, E. T., & Kelly, J. W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00004-5 · Cited by 4
Proteomics of Alzheimer's disease: Unveiling protein dysregulation in complex neuronal systems
Vosseller, K. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700323 · Cited by 4
Metabolic Syndrome as a Risk Factor for Alzheimer Disease
Farooqui, A. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7318-3_8 · Cited by 5
Molecular Aspects of Memory Dysfunction in Alzheimer’s Disease
Chin, J., Roberson, E. D., & Mucke, L. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00015-2 · Cited by 5
Mijalkov, M., Veréb, D., Canal-García, A., Volpe, G., Pereira, J. B., & Initiative, A. D. N. (2023) · Neuroscience Insights · doi:10.1177/26331055231161625 · Cited by 3
Metadata
- Authors
- Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- University of Southern California (US)
- Acumen Pharmaceuticals (United States) (US)
- Corresponding author
- Klein, William L.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2004-11-10
- Volume
- 24
- Issue
- 45
- Pages
- 10191-10200
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6730194
- OpenAlex
- W2162807572
- Cited by
- 954
- References
- 64
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 24 · 2023: 41 · 2022: 35 · 2021: 28 · 2020: 26 · 2019: 32 · 2018: 41 · 2017: 50 · 2016: 51 · 2015: 50 · 2014: 54 · 2013: 65 · 2012: 59
- FWCI
- 25.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Illinois Department of Public Health
- Northwestern University
- National Institutes of Health (AG11385)
- National Institute on Aging (R01 AG11385, P30AG13854, R01AG022547, R01-AG22547, R01AG011385, R03AG022237, R01-AG18877, P30AG013854, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, synaptic targeting, long-term potentiation, synaptic plasticity, PSD-95, Arc, hippocampal neurons, memory loss, early Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Animals, Binding Sites, Cerebral Cortex, Cerebrospinal Fluid Proteins, Chromatography, High Pressure Liquid, Cytoskeletal Proteins, Female, Hippocampus, Humans, Male, Nerve Tissue Proteins, Neurons, Peptide Fragments, Protein Binding, Synapses, Tissue Extracts, Amyloid beta-Peptides, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
